AuntMinnie.com staff writersBreastVolpara adds Custin to board of directorsBreast imaging software developer Volpara Solutions has appointed Ann Custin to its board as an independent, nonexecutive director, effective September 1.August 24, 2021MRILow BPE suppression on MRI may indicate poor treatment responseA lack of background parenchymal enhancement (BPE) suppression on contrast breast MRI during and after chemotherapy may suggest poor treatment response in hormone receptor-positive breast cancer patients, according to a study published August 24 in Radiology.August 24, 2021MRIHyperfine appoints new CFOPortable MRI developer Hyperfine has appointed Alok Gupta as its new chief financial officer (CFO).August 23, 2021Digital X-RayFujifilm lands DR supply contract from U.S. NavyFujifilm Medical Systems USA has won a 10-year sole-source contract to supply its digital radiography (DR) systems to the U.S. Navy.August 23, 2021Image ProcessingDiA secures $14M in new fundingUltrasound artificial intelligence software developer DiA Imaging Analysis has garnered $14 million in funding from new and existing investors.August 23, 2021Molecular ImagingCurium files IND application for prostate PET agentNuclear medicine firm Curium has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for its copper-64 PSMA I&T diagnostic radiopharmaceutical.August 23, 2021PACS/VNACovera Health nets $25M in financingClinical analytics Covera Health has received $25 million in a series C financing round.August 23, 2021Molecular ImagingLightpoint, Telix ink collaboration agreementLuminescence imaging technology developer Lightpoint Medical has signed a collaboration agreement with radiopharmaceutical developer Telix Pharmaceuticals.August 22, 2021Clinical NewsAnthem to cover Hologic's Acessa procedure for uterine fibroidsAnthem Blue Cross will now cover Hologic's Acessa radiofrequency ablation procedure for treating uterine fibroids.August 22, 2021MRIWhen is the best time to stop following low-risk prostate cancer?There are a variety of factors associated with the discontinuation of active surveillance of men with low-risk prostate cancer, both demographic and clinical, according to a study published August 20 in the Journal of Urology.August 22, 2021Previous PagePage 223 of 3774Next PageTop StoriesNuclear MedicineGenetic mutations linked to poor outcomes in Pluvicto patientsTP53, PTEN, and RB1 mutations may serve as prognostic biomarkers.Womens ImagingAI support leads to more cancers found on DBTCTPROMISE: Women face higher heart disease risk at lower plaque burdensMolecular ImagingPET predicts faster cognitive decline in women than menSponsor ContentHow Agentic AI Is Transforming Radiology Ops
